A Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome

F1J-MC-HMGW -

The purpose of this study is to determine whether duloxetine is safe and effective in the treatment of adolescents with Juvenile Primary Fibromyalgia Syndrome (JPFS). This trial consists of two distinct study periods; a blinded treatment period of 13 weeks and an open label extension period of 26 weeks.

Trial Summary

Age Range
13 - 17 years
Conditions the trial is for
Juvenile Primary Fibromyalgia Syndrome
What the trial is testing?
Duloxetine
Could I receive a Placebo?
Yes
Enrollment Goal
184
Trial Dates
Mar 1, 2011 - Nov 28, 2017
How long will I be in the trial?
Your participation could last up to 39 weeks and include 15 visits to the study center.
Trial Phase
III

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.